Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Clinical trial NCT04510610 · UNKNOWN
Trial details
- NCT number
- NCT04510610
- Sponsor
- Chinese PLA General Hospital
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-01
- Primary completion
- 2022-01-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.